IDEAYA Biosciences Prices Public Offering of Common Stock
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Source: PRnewswire
- Offering Size: IDEAYA Biosciences has priced its public offering at $27.00 per share, planning to sell 5,555,556 shares of common stock and 5,555,576 pre-funded warrants, with expected gross proceeds of approximately $300 million, indicating strong demand in the capital markets.
- Underwriter Lineup: The offering is being managed by J.P. Morgan, Jefferies, TD Cowen, UBS Investment Bank, and Cantor, reflecting market confidence in IDEAYA and its influence in the biotech sector.
- Additional Purchase Option: IDEAYA has granted underwriters a 30-day option to purchase up to an additional 1,666,669 shares at the public offering price, providing the company with flexibility for further financing.
- Closing Timeline: The offering is expected to close on June 10, 2026, subject to customary closing conditions, and if successful, will provide crucial funding for the company's future R&D and market expansion efforts.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IDYA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IDYA
Wall Street analysts forecast IDYA stock price to rise
15 Analyst Rating
13 Buy
2 Hold
0 Sell
Strong Buy
Current: 28.070
Low
30.00
Averages
49.86
High
79.00
Current: 28.070
Low
30.00
Averages
49.86
High
79.00
About IDYA
IDEAYA Biosciences, Inc. is a medicine oncology company. The Company is engaged in the discovery, development, and commercialization of transformative therapies for cancer. Its product candidates focus on synthetic lethality and antibody-drug conjugates (ADCs) for molecularly defined solid tumor indications. Its product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE161 (PARG), IDE275 (Werner Helicase) and IDE705 (Pol Theta Helicase). Darovasertib is a clinical stage, potent and selective small molecule inhibitor of PKC, a protein kinase that functions downstream of the GTPases GNAQ and GNA11. IDE397 is an oral small molecule inhibitor of methionine adenosyl transferase 2a (MAT2A). IDE161 is an oral small molecule poly (ADP-ribose) glycohydrolase (PARG) inhibitor. IDE275 is an oral small molecule inhibitor of the helicase domain of the Werner protein (WRN), a RecQ enzyme involved in the maintenance of genome integrity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
IDEAYA Biosciences Completes Public Offering Raising $345 Million
- Offering Size: IDEAYA Biosciences successfully closed its public offering of 7,222,225 shares at $27.00 per share, raising approximately $345 million in gross proceeds, significantly enhancing its financial capacity to support ongoing R&D initiatives.
- Underwriter Performance: The offering was managed by J.P. Morgan, Jefferies, TD Cowen, UBS Investment Bank, and Cantor, reflecting strong market confidence in IDEAYA and laying the groundwork for future capital market activities.
- Registration Compliance: The public offering was conducted under an automatically effective shelf registration statement on Form S-3, ensuring compliance and streamlining the offering process, which enhances investor trust.
- Strategic Development: IDEAYA is focused on precision oncology, and the proceeds from this offering will be used to advance its research in synthetic lethality and antibody-drug conjugates (ADCs), further solidifying its market position in cancer therapeutics.
See More
IDEAYA Biosciences Prices Public Offering at $27 per Share
- Offering Size: IDEAYA Biosciences announced a public offering of 5.56 million shares priced at $27.00 each, with expected gross proceeds of approximately $300 million, which will significantly bolster the company's funding for R&D and clinical trials.
- Pre-Funded Warrants: The company also issued pre-funded warrants at $26.9999 each, allowing for the purchase of an additional 5.56 million shares, enhancing capital-raising flexibility and potential cash inflow.
- Underwriter Arrangement: J.P. Morgan, Jefferies, TD Cowen, UBS Investment Bank, and Cantor are acting as joint book-running managers for the offering, indicating strong market confidence and support for IDEAYA.
- Stock Performance: IDEAYA's stock has traded between $20.50 and $39.28 over the past year, closing at $31.48 on Monday with an 11.28% increase, although it fell 4.83% to $29.96 in after-hours trading, reflecting mixed market reactions to the offering news.
See More
IDEAYA Biosciences Raises $300M in Public Offering
- Offering Size: IDEAYA Biosciences has announced an underwritten public offering aimed at raising approximately $300 million by selling 5.56 million shares of common stock at a price of $27 per share, indicating strong market demand for the company.
- Pre-Funded Warrants: The company is also issuing pre-funded warrants to purchase an additional 5.56 million shares at $26.9999 per warrant with a nominal exercise price of $0.0001 per share, enhancing its capital-raising capabilities.
- Underwriter's Option: IDEAYA has granted underwriters a 30-day option to purchase up to an additional 1.67 million shares at the public offering price, providing the company with additional financial flexibility.
- Transaction Timeline: The transaction is expected to close on or about June 10, 2026, subject to customary closing conditions, reflecting the company's robust planning in capital operations.
See More
Tango Therapeutics Shares Surge Over 50% on Positive Trial Data
- Positive Clinical Trial Data: Tango Therapeutics' Vopimetostat shows a 90% six-month progression-free survival rate in its Phase 1/2 trial for pancreatic cancer, prompting plans to advance to Phase 3, thereby enhancing its competitive edge in cancer treatment.
- Aspire Biopharma Growth Prospects: Aspire Biopharma aims to file its NDA for high-dose sublingual aspirin by the end of 2026, and its acquisition of Dura Driver Control Systems is expected to generate over $200 million in revenue, further solidifying its market position.
- Alvotech FDA Application Progress: Alvotech's AVT16 biosimilar application has been accepted for FDA review, which is anticipated to significantly bolster its competitive stance in the biopharmaceutical market, particularly for treating Crohn's disease and ulcerative colitis.
- Zevra Patent Protection Enhancement: Zevra Therapeutics' MIPLYFFA has been listed in the Orange Book by the U.S. Patent Office, with patent protection extending to 2041, expected to significantly enhance its exclusivity and revenue potential in the rare disease market.
See More
IDEAYA Biosciences Prices Public Offering of Common Stock
- Offering Size: IDEAYA Biosciences has priced its public offering at $27.00 per share, planning to sell 5,555,556 shares of common stock and 5,555,576 pre-funded warrants, with expected gross proceeds of approximately $300 million, indicating strong demand in the capital markets.
- Underwriter Lineup: The offering is being managed by J.P. Morgan, Jefferies, TD Cowen, UBS Investment Bank, and Cantor, reflecting market confidence in IDEAYA and its influence in the biotech sector.
- Additional Purchase Option: IDEAYA has granted underwriters a 30-day option to purchase up to an additional 1,666,669 shares at the public offering price, providing the company with flexibility for further financing.
- Closing Timeline: The offering is expected to close on June 10, 2026, subject to customary closing conditions, and if successful, will provide crucial funding for the company's future R&D and market expansion efforts.
See More
IDEAYA Biosciences Prices Public Offering of Common Stock
- Offering Size: IDEAYA Biosciences is set to sell 5,555,556 shares of common stock and 5,555,576 pre-funded warrants at a price of $27.00 per share and $26.9999 per warrant, respectively, with expected gross proceeds of approximately $300 million, indicating strong market demand for the company's equity.
- Underwriter Lineup: The offering is managed by a consortium including J.P. Morgan, Jefferies, TD Cowen, UBS Investment Bank, and Cantor, with Wedbush PacGrow as the lead manager, reflecting significant confidence in IDEAYA's position within the biotech sector.
- Additional Option: IDEAYA has granted underwriters a 30-day option to purchase an additional 1,666,669 shares at the public offering price, providing the company with flexibility for further capital raising, which could enhance its financial structure.
- Closing Timeline: The offering is expected to close around June 10, 2026, subject to customary closing conditions, and if successful, will provide crucial funding for the company's ongoing research and market expansion efforts.
See More
IDEAYA Biosciences Completes Public Offering Raising $345 Million
- Offering Size: IDEAYA Biosciences successfully closed its public offering of 7,222,225 shares at $27.00 per share, raising approximately $345 million in gross proceeds, significantly enhancing its financial capacity to support ongoing R&D initiatives.
- Underwriter Performance: The offering was managed by J.P. Morgan, Jefferies, TD Cowen, UBS Investment Bank, and Cantor, reflecting strong market confidence in IDEAYA and laying the groundwork for future capital market activities.
- Registration Compliance: The public offering was conducted under an automatically effective shelf registration statement on Form S-3, ensuring compliance and streamlining the offering process, which enhances investor trust.
- Strategic Development: IDEAYA is focused on precision oncology, and the proceeds from this offering will be used to advance its research in synthetic lethality and antibody-drug conjugates (ADCs), further solidifying its market position in cancer therapeutics.
See More
IDEAYA Biosciences Prices Public Offering at $27 per Share
- Offering Size: IDEAYA Biosciences announced a public offering of 5.56 million shares priced at $27.00 each, with expected gross proceeds of approximately $300 million, which will significantly bolster the company's funding for R&D and clinical trials.
- Pre-Funded Warrants: The company also issued pre-funded warrants at $26.9999 each, allowing for the purchase of an additional 5.56 million shares, enhancing capital-raising flexibility and potential cash inflow.
- Underwriter Arrangement: J.P. Morgan, Jefferies, TD Cowen, UBS Investment Bank, and Cantor are acting as joint book-running managers for the offering, indicating strong market confidence and support for IDEAYA.
- Stock Performance: IDEAYA's stock has traded between $20.50 and $39.28 over the past year, closing at $31.48 on Monday with an 11.28% increase, although it fell 4.83% to $29.96 in after-hours trading, reflecting mixed market reactions to the offering news.
See More
IDEAYA Biosciences Raises $300M in Public Offering
- Offering Size: IDEAYA Biosciences has announced an underwritten public offering aimed at raising approximately $300 million by selling 5.56 million shares of common stock at a price of $27 per share, indicating strong market demand for the company.
- Pre-Funded Warrants: The company is also issuing pre-funded warrants to purchase an additional 5.56 million shares at $26.9999 per warrant with a nominal exercise price of $0.0001 per share, enhancing its capital-raising capabilities.
- Underwriter's Option: IDEAYA has granted underwriters a 30-day option to purchase up to an additional 1.67 million shares at the public offering price, providing the company with additional financial flexibility.
- Transaction Timeline: The transaction is expected to close on or about June 10, 2026, subject to customary closing conditions, reflecting the company's robust planning in capital operations.
See More
Tango Therapeutics Shares Surge Over 50% on Positive Trial Data
- Positive Clinical Trial Data: Tango Therapeutics' Vopimetostat shows a 90% six-month progression-free survival rate in its Phase 1/2 trial for pancreatic cancer, prompting plans to advance to Phase 3, thereby enhancing its competitive edge in cancer treatment.
- Aspire Biopharma Growth Prospects: Aspire Biopharma aims to file its NDA for high-dose sublingual aspirin by the end of 2026, and its acquisition of Dura Driver Control Systems is expected to generate over $200 million in revenue, further solidifying its market position.
- Alvotech FDA Application Progress: Alvotech's AVT16 biosimilar application has been accepted for FDA review, which is anticipated to significantly bolster its competitive stance in the biopharmaceutical market, particularly for treating Crohn's disease and ulcerative colitis.
- Zevra Patent Protection Enhancement: Zevra Therapeutics' MIPLYFFA has been listed in the Orange Book by the U.S. Patent Office, with patent protection extending to 2041, expected to significantly enhance its exclusivity and revenue potential in the rare disease market.
See More
IDEAYA Biosciences Prices Public Offering of Common Stock
- Offering Size: IDEAYA Biosciences has priced its public offering at $27.00 per share, planning to sell 5,555,556 shares of common stock and 5,555,576 pre-funded warrants, with expected gross proceeds of approximately $300 million, indicating strong demand in the capital markets.
- Underwriter Lineup: The offering is being managed by J.P. Morgan, Jefferies, TD Cowen, UBS Investment Bank, and Cantor, reflecting market confidence in IDEAYA and its influence in the biotech sector.
- Additional Purchase Option: IDEAYA has granted underwriters a 30-day option to purchase up to an additional 1,666,669 shares at the public offering price, providing the company with flexibility for further financing.
- Closing Timeline: The offering is expected to close on June 10, 2026, subject to customary closing conditions, and if successful, will provide crucial funding for the company's future R&D and market expansion efforts.
See More
IDEAYA Biosciences Prices Public Offering of Common Stock
- Offering Size: IDEAYA Biosciences is set to sell 5,555,556 shares of common stock and 5,555,576 pre-funded warrants at a price of $27.00 per share and $26.9999 per warrant, respectively, with expected gross proceeds of approximately $300 million, indicating strong market demand for the company's equity.
- Underwriter Lineup: The offering is managed by a consortium including J.P. Morgan, Jefferies, TD Cowen, UBS Investment Bank, and Cantor, with Wedbush PacGrow as the lead manager, reflecting significant confidence in IDEAYA's position within the biotech sector.
- Additional Option: IDEAYA has granted underwriters a 30-day option to purchase an additional 1,666,669 shares at the public offering price, providing the company with flexibility for further capital raising, which could enhance its financial structure.
- Closing Timeline: The offering is expected to close around June 10, 2026, subject to customary closing conditions, and if successful, will provide crucial funding for the company's ongoing research and market expansion efforts.
See More
